Is Ixabepilone effective in patients with paclitaxel resistance?

Ixabepilone () is a new anti-tumor drug that is an epiline protein inhibitor and is designed to overcome the resistance of traditional taxanes. It is a semi-synthetic derivative of epothilone B. Its mechanism is similar to taxanes. It can stabilize the microtubule structure and prevent its depolymerization, thereby blocking the mitosis of cancer cells and inducing apoptosis. However, the molecular structure of ixabepilone has a unique advantage—it is insensitive to the P-glycoprotein (P-gp)-mediated drug efflux pump, so it can still maintain anti-tumor activity in patients who have failed paclitaxel or docetaxel.

Overseas studies andFDA-approved indications both show that ixabepilone combined with capecitabine is used to treat patients with locally advanced or metastatic breast cancer that is resistant to anthracyclines and taxanes, especially those who have received standard chemotherapy but have experienced disease progression. For patients who are resistant to both anthracyclines, taxanes, and capecitabine, ixabepilone monotherapy also shows certain efficacy. Its unique mechanism of cytotoxic action makes it an important alternative for patients with paclitaxel resistance.

From a molecular level, ixabepilone can form a more stable complex with β-tubulin at the microtubule binding site. Even if cancer cells upregulate drug resistance-related proteins, it is difficult to expel them out of the cells. This structural difference explains its therapeutic advantage in drug-resistant breast cancer patients. In addition, unlike traditional chemotherapy, ixabepilone also shows activity in some patients with triple-negative breast cancer (TNBC), providing a new clinical treatment direction.

In summary, ixabepilone still has significant efficacy in patients with paclitaxel-resistant breast cancer, and is especially suitable for patients with progressive disease and limited chemotherapy options. It represents another advance in microtubule-targeting drugs and provides a new therapeutic window in the field of chemotherapy resistance.

Reference materials:https://www.drugs.com/mtm/ixabepilone.html